SecurityIZEA / IZEA Inc. (46603N301)
President and CEOMurphy Edward H
IndustryAdvertising
Institutional Owners15
Institutional Shares1,763,245 - 16.53%
Common Shares Outstanding10,665,698 shares (as of 2018-06-30)
Institutional Value$ 1,721,000 USD

Institutional Stock Ownership and Shareholders

IZEA / IZEA Inc. Institutional Ownership

IZEA Inc. (NASDAQ:IZEA) has 15 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 1,763,245 shares. Largest shareholders include Perkins Capital Management Inc, AWM Investment Company, Inc., Vanguard Group Inc, Royce & Associates LLC, Morgan Stanley, Macquarie Group Ltd, Deutsche Bank Ag\, Panagora Asset Management Inc, Geode Capital Management, Llc, and Virtu Financial LLC.
IZEA Inc. (NASDAQ:IZEA) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-08-14 13F-HR GEODE CAPITAL MANAGEMENT, LLC 24,901 24,901 0.00 91 23 -74.73
2018-08-14 13F-HR MACQUARIE GROUP LTD 21,256 45,040 111.89 78 43 -44.87
2018-08-14 13F-HR VANGUARD GROUP INC 305,678 95,161 -68.87 1,119 90 -91.96
2018-07-24 13F-HR ACADIAN ASSET MANAGEMENT LLC 21,791 0 -100.00 79 0 -100.00
2018-08-14 13F-HR MORGAN STANLEY 68 50,377 73,983.82 0 48
2018-08-09 13F-HR BlackRock Inc. 3,865 4,221 9.21 14 4 -71.43
2018-07-30 13F-HR/A Virtu Financial LLC 0 15,359 0 15
2018-08-14 13F-HR UBS Group AG 374 0 -100.00 1 0 -100.00
2018-08-09 13F-HR Royce & Associates LLC 161,176 85,870 -46.72 590 82 -86.10
2018-08-14 13F-HR PANAGORA ASSET MANAGEMENT INC 30,145 29
2018-08-14 13F-HR/A CITADEL ADVISORS LLC 13,673 13
2018-08-02 13F-HR PERKINS CAPITAL MANAGEMENT INC 107,595 827,595 669.18 394 786 99.49
2018-08-14 13F-HR DEUTSCHE BANK AG\ 1,300 40,000 2,976.92 4 38 850.00
2018-08-14 13F-HR ROYAL BANK OF CANADA 6 0 -100.00 0 0
2018-07-30 13F-HR Raymond James Financial Services Advisors, Inc. 10,035 10
2018-08-07 13F-HR IFP Advisors, Inc 1,000 0 -100.00 4 0 -100.00
2018-07-17 13F-HR ESSEX INVESTMENT MANAGEMENT CO LLC 84,510 0 -100.00 309 0 -100.00
2017-02-10 13F-HR BlackRock Fund Advisors 11,586 12,228 5.54 68 55 -19.12
2017-02-10 13F-HR BlackRock Investment Management, LLC 755 755 0.00 4 3 -25.00
2018-08-14 13F-HR TWO SIGMA SECURITIES, LLC 11,035 0 -100.00 40 0 -100.00
2018-08-14 13F-HR A.R.T. Advisors, LLC 16,407 0 -100.00 60 0 -100.00
2018-08-14 13F-HR BARCLAYS PLC 10,300 0 -100.00 38 0 -100.00
2018-08-09 13F-HR AWM Investment Company, Inc. 543,216 507,885 -6.50 1,988 482 -75.75

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

19h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

19h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

21h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

Opko Health: If These SEC Charges Were Surprising Then You Haven't Been Paying Attention

2018-09-11 seekingalpha
Opko's stock is now halted following SEC charges alleging fraud by both the company and its Chairman & CEO Phil Frost. (101-6)

IZEA Inc. (IZEA) CEO Ted Murphy on Q2 2018 Results - Earnings Call Transcript

2018-08-15 seekingalpha
Ladies and gentlemen, greetings and welcome to the IZEA Inc., Second Quarter 2018 Earnings Call. At this time all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. (43-2)

Facebook Roundup: UK, Germany, India, Kids, Openbook

2018-07-25 zacks
Fresh news about Russia’s link to Cambridge Analytica, Facebook (FB - Free Report) CEO Mark Zuckerberg’s comments on Holocaust denial in Germany, WhatsApp’s role in misinformation-based killings in India, the promise of a proactive approach to kids’ safety and a new social network called Opnebook were the top stories from last week. Here are the details- (54-0)

Tread Carefully After the IZEA Stock Rally

2018-07-17 investorplace
What a Thursday it was for Izea (NASDAQ:IZEA). The nano-cap marketing firm saw its stock rise 174% after it announced a deal to acquire TapInfluence. (83-2)

IZEA's (IZEA) CEO Ted Murphy on Q4 2017 Results - Earnings Call Transcript

2018-04-20 seekingalpha
Greetings and welcome to the IZEA’s Incorporated Q4 and Annual 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. (1-2)

CUSIP: 46603N301